IRVINE, Calif., November 22, 2016 – BIOLASE, Inc., (NASDAQ: BIOL) the global leader in dental lasers, announced today it will be previewing Epic Pro™, an all-new, innovative dental diode laser system at the upcoming Greater New York Dental Meeting to be held November 25-30 at the Jacob Javits Convention Center in New York City.
The Epic Pro, which offers the most laser power of any diode laser in dentistry, is the first product to be introduced resulting from BIOLASE’s strategic development agreement with IPG Photonics. The newest addition to the Epic family of dental soft-tissue lasers, Epic Pro features several new innovations that are industry-firsts:
· A new super pulse technology for more precise, enhanced laser tissue cutting;
· Real-time automatic power control to enhance speed and consistency when performing surgery;
· Pre-initiated, bendable, disposable tips with new smart tip technology to ensure tip performance and quality.
The new systems will provide even more predictable, minimally-invasive solutions for soft-tissue management than is currently offered by its market-leading Epic X product and other diode lasers on the market. It represents the first premium grade diode laser from BIOLASE and an important example of the kind of innovation BIOLASE is working on, both with IPG and through its internal product development efforts, noted BIOLASE President and CEO Harold C. Flynn, Jr.
“The introduction of Epic Pro is an important milestone for our company. We are proud to be expanding our diode laser range to incorporate new innovations that will allow dental professionals to manage soft tissue with lasers in a way that no other diode laser has achieved,” Flynn said. “Epic Pro represents our ongoing commitment to elevating the standard of care in dentistry, and achieving better patient reported outcomes while enabling clinicians to realize better business returns. We are very excited about the possibilities offered to our customers by this new technology addition to our portfolio.”
The Epic Pro laser system is currently undergoing premarket notification review by FDA for dental / surgical operations, intended for use in contact and non-contact techniques for incision, excision, vaporization, ablation, hemostasis, or coagulation of intraoral and extra-oral soft tissue (including marginal and interdental gingiva and epithelial lining of free gingiva). It is not yet available for sale within the United States.
Visit the BIOLASE booth #422 at the Greater New York Dental Meeting to preview this latest breakthrough in soft-tissue laser technology.
